Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Jun. 30, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | Rule 10b5-1 Trading Arrangements During the three months ended June 30, 2026, none of our directors or officers, as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, other than as set forth below: • Lance Kurata, our Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement as of May 15, 2026. Mr. Kurata's trading arrangement provides for the exercise of options to purchase up to 30,000 shares of common stock and the subsequent sale of up to an aggregate of 30,000 shares of common stock, . •
Dr. Padmanabh Chivukula, Chief Scientific Officer and Chief Operating Officer, adopted a Rule 10b5-1 trading arrangement on May 14, 2026. Dr. Chivukula’s trading arrangement provides for the sale of up to an aggregate of 60,000 shares of common stock, . |
| Rule 10b5-1 Arrangement Adopted | false |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Lance Kurata [Member] | |
| Trading Arrangements, by Individual | |
| Name | Lance Kurata |
| Title | Chief Legal Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | May 15, 2026 |
| Arrangement Duration | 230 days |
| Aggregate Available | 30,000 |
| Dr. Padmanabh Chivukula [Member] | |
| Trading Arrangements, by Individual | |
| Name | Dr. Padmanabh Chivukula |
| Title | Chief Scientific Officer and Chief Operating Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | May 14, 2026 |
| Arrangement Duration | 505 days |
| Aggregate Available | 60,000 |